… BRAF/MEK inhibitors (BRAF/MEKi) for BRAF V600 -mutant metastatic melanoma, and we
explore the three major effectors of BRAF/MEK inhibitor … BRAF-mutated metastatic melanoma. …

… unique biochemical effects observed with BRAF inhibitors, this combination appears to be
… with either a BRAF or MEK inhibitor. We believe that the combination of dabrafenib and …

… , improves the overall survival of patients with BRAF V600 mutation–positive metastatic …
The combination of BRAF and MEK inhibition, as compared with single-agent BRAF inhibition, …

… Taking together these data combining BRAF/MEK inhibitors with ICPIs may help not …
BRAF/MEK inhibition may be too late. Even in cases where resistance to both BRAF/MEK inhibitors …

… combined BRAF and MEK inhibition provided significant advantage in ORR, PFS and OS over
BRAF inhibition … combined BRAF and MEK inhibition will become the mainstay therapy for …

… Even though combined BRAF and MEK inhibition led to a decrease in MAPK pathway
activity in all patients, the degree of MAPK inhibition achieved remains suboptimal. Additional …

… Preclinical models suggest that combining BRAF and MEK inhibitors with PD-1 blockade
therapy improves antitumor activity 4,5,6 , which may provide additional treatment options for …

… demonstrated that initial therapy with combined BRAF and MEK inhibition is more effective
in BRAF V600 -mutant melanoma than single-agent BRAF inhibitors. This study assessed the …

… BRAF and MEK inhibitor combinations have been approved for use in various cancers by …
for various BRAF plus MEK combination regimens in three cancer types with underlying BRAF …

… trials combining inhibitors of both MEK and mutant BRAF kinase … BRAF inhibitor monotherapy.
In this review, we discuss existing clinical trial data on BRAF and MEK inhibitors together …